Birch allergoid

Birch allergoid (brand name: LAIS Birch tablets) is a sublingual immunotherapy (SLIT) product developed by Lofarma. Its active ingredient is a carbamylated monomeric allergoid (CMA) derived from birch pollen, specifically targeting the immune response to birch tree pollen allergens (including the major birch pollen allergen Bet v 1). As an allergoid-based biologic/immunotherapy, it is classified as a modified allergen extract (biologic modality). It is indicated for the treatment of tree pollen-induced allergic rhinoconjunctivitis and mild controlled seasonal allergic asthma in adults. A Phase 3 clinical trial was completed in Italy evaluating the efficacy and safety of LAIS Birch tablets versus placebo in adults with tree pollen-induced allergic rhinoconjunctivitis, with or without mild controlled seasonal allergic asthma. The product is part of Lofarma's broader LAIS platform of carbamylated monomeric allergoid products, which also includes LAIS 2-tree allergoid tablets (covering birch and alder) and injectable formulations (LAIS-in).

Brand names

LAIS BirchLAIS Birch tablets

Other names

carbamylated monomeric birch pollen allergoidcarbamylated monomeric tree pollen dropsLAIS Birch-Alder tabletsLais Frühblüher sublingual dropsTree-pollen allergoid - Lofarma